Immune globulin - Evolve Biologics
Alternative Names: 10% intravenous immunoglobulin - Evolve Biologics; 10% IVIG - Evolve Biologics; Human Immunoglobulin - Evolve Biologics; Intravenous immunoglobulin - Evolve Biologics; PlasmaCap IGLatest Information Update: 22 Apr 2022
At a glance
- Originator Therapure Biopharma
- Developer Evolve Biologics
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Immunodeficiency disorders
Most Recent Events
- 22 Apr 2022 Phase III development in Immunodeficiency disorders is ongoing in USA and Canada (Evolve Biolgics website, April 2022)
- 23 Feb 2022 Phase III development in Immunodeficiency disorders is ongoing in USA and Canada (Evolve Biolgics website, February 2022)
- 22 Apr 2021 Evolve Biologics plans regulatory submissions in USA and Canada, in 2025 (Evolve Biolgics website, March,